300
Participants
Start Date
October 31, 2007
Primary Completion Date
September 30, 2010
Study Completion Date
December 31, 2010
Bortezomib
"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
Thalidomide
"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
Rigshospitalet, Copenhagen
Herlev University Hospital, Herlev
Stavanger Universitetssykehus, Stavanger
Odense University Hospital, Odense
Århus University Hospital, Aarhus
Ålborg university Hospital, Aalborg
St Göran Hospital, Stockholm
Malmö University Hospital, Malmo
Lund University Hospital, Lund
Helsingborg Hospital, Helsingborg
Växjö Hospital, Vaxjo
Sahlgrenska University Hospital, Gothenburg
Mölndal hospital, Mölndal
Uddevalla Hospital, Uddevalla
Lidköping Hospital, Lidköping
Skövde Hospital, Skövde
Örebro University Hospital, Örebro
Västerås Hospital, Västerås
Uppsala University Hospital, Uppsala
Falun Hospital, Falun
Gävle Hospital, Gävle
Sundsvall Hospital, Sundsvall
Örnsköldsvik Hospital, Örnsköldsvik
Norrland University Hospital, Umeå
Ullevål Sykehus, Oslo
Diakonhjemmet, Oslo
Trondheim University Hospital, Trondheim
Nordic Myeloma Study Group
OTHER